Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of IBI343 versus placebo, each with best supportive care, in CLDN18.2-positive advanced pancreatic cancer after at least two prior systemic therapies
CTR20252528Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- Aug 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of arcotatug tavatecan in pancreatic cancer (PC), sponsored by InnoCare Pharma. Started Aug 2025; status: active.
02
Drugs
arcotatug tavatecan
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20252528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252528.